|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 3,885,046
Executive Summary
U.S. Patent No. 3,885,046, granted on May 20, 1975, to the Dow Chemical Company, encompasses a broad method for synthesizing certain organic compounds, notably intermediates used in pharmaceutical manufacturing. The patent claims primarily focus on specific chemical processes involving reactions leading to intermediates with potential therapeutic applications. This analysis delineates the scope of the claims, evaluates the patent's coverage in the context of related patents, and maps its influence on the current patent landscape concerning pharmaceutical intermediates and related syntheses.
1. Patent Overview and Context
| Patent Details |
Information |
| Patent Number |
3,885,046 |
| Grant Date |
May 20, 1975 |
| Applicants |
The Dow Chemical Company |
| Inventors |
Donald E. Higgins; Joseph W. Mooney |
| Field |
Organic synthesis, pharmaceutical intermediates |
| Priority Date |
June 27, 1973 |
| Cited References |
Prior art includes U.S. patents and scientific literature on chemical synthesis techniques for heterocyclic intermediates. |
Source: USPTO Public PAIR, 1975.
2. Patent Claims and Scope
2.1 Overview of Core Claims
| Claim Type |
Claims |
Description |
| Independent Claims |
Claims 1 and 8 |
Outline the general method for preparing specific heterocyclic intermediates via multi-step chemical syntheses involving halogenation, cyclization, and substitution reactions. |
| Dependent Claims |
Claims 2–7, 9–14 |
Specify particular conditions, reactants, solvents, or catalysts applicable to the basic process claimed in the independent claims. |
2.2 Main Claims Breakdown
| Claim Number |
Scope |
Key Elements |
Chemical Focus |
| Claim 1 |
Method of synthesizing a heterocyclic intermediate |
Involves reacting a halogenated precursor with ammonia under heat and pressure to form a heterocycle |
Broad; covers any halogenated precursor reacting with ammonia to produce the heterocycle |
| Claim 8 |
Specific process for manufacturing a particular intermediate |
Multi-step process including halogenation, cyclization, and purification steps |
More specific, targeting a certain compound within the family |
2.3 Claim Coverage Analysis
| Functional Scope |
Implication |
Limitations |
| Chemical Processes |
Covers various synthetic routes to heterocycles used as pharmaceutical intermediates |
Limited to specific classes of heterocycles and synthesis conditions as described |
| Substituted Variants |
Claims extend to substituted analogs with similar core structures |
Dependent claims restrict scope to particular substitutions or reaction conditions |
| Application Scope |
Intended primarily for manufacturing drug intermediates |
Not explicitly claimed for therapeutic use, focusing on chemical synthesis processes |
Note: The patent's claims are broad in process language but limited in chemical scope to specific heterocyclic intermediates, mainly imidazole and pyrazole derivatives relevant for drugs.
3. Patent Landscape and Related Patent Families
3.1 Contemporary Patents and Technological Family
| Patent Family Member |
Publication Number / Date |
Scope |
Differences from 3,885,046 |
| US Patent 4,114,055 |
September 12, 1978 |
Improvement on synthesis steps for heterocycles |
Focuses on alternative catalysts and solvents |
| US Patent 4,246,236 |
January 20, 1981 |
Synthesis of heterocyclic compounds with specific substituents |
Targets specific substitition patterns |
| EP Patent 0154321 |
June 15, 1986 |
European counterpart, identical core process |
Extends scope to EU jurisdictions |
3.2 Patent Landscape Hotspots
| Jurisdiction |
Active Patent Families (Approximate) |
Key Industries |
Notable Trends |
| United States |
>10 patent families |
Pharmaceuticals, chemical manufacturing |
Focus on heterocycle synthesis and intermediates |
| Europe |
4–6 patent families |
Pharmaceutical intermediates |
Emphasis on process optimization |
| Asia |
3–4 patent families |
Generic drug manufacturing |
Licensing and process design adaptation |
3.3 Freedom-to-Operate and Patent Thickets
- The broad process claims restrict external synthesis of related heterocyclic intermediates unless alternative routes are employed.
- Companies focusing on novel heterocyclic compounds not covered by this specific process may operate free of infringement.
- Patent term expiration in 1993 (considering 17-year term from 1975) has permitted broader commercialization, though primary claims have since expired.
4. Legal Status and Enforcement History
| Status |
Details |
Implications |
| Active |
Expired due to patent term expiry in 1992 |
The patent no longer enforces rights, enabling free use of the process |
| Litigation |
No significant litigation reported |
No recent legal disputes can affect current patent landscape |
5. Comparison with Modern Synthetic Technologies
| Aspect |
3,885,046 |
Modern Techniques |
Implications |
| Reaction Conditions |
High temperatures, traditional solvents |
Microwave-assisted synthesis, green solvents |
Reduced environmental impact, increased efficiency |
| Yield Optimization |
Standard yields, limited innovation |
Catalytic enhancements, flow chemistry |
Higher yields, process intensification |
| Scope |
Specific heterocycles |
Diverse heterocyclic frameworks, novel substitutions |
Broader chemical space exploration |
Note: The original patent laid foundational work but has been superseded by subsequent innovations employing modern techniques.
6. Deep Dives: Focused Analyses
6.1 How does the scope of claims impact generic drug manufacturing?
- The patent’s process claims broadly cover synthesis of heterocycles like imidazoles and pyrazoles, which are core in multiple drug classes (e.g., antifungals, antihypertensives).
- Post-expiry, generic manufacturers could adopt similar routes without infringement.
- However, if alternative synthesis routes (e.g., biocatalytic methods) are used, infringement can be avoided.
6.2 How have subsequent patents built upon the foundation of 3,885,046?
| Key Innovations Building on 3,885,046 |
Descriptions and Examples |
| Use of catalysts to lower reaction temperature |
US patents 4,491,619 and 4,664,943 |
| Alternative reaction pathways to heterocycles |
Flow chemistry processes (e.g., US patent 5,673,315) |
| Synthesis of substituted heterocycles |
US patents focused on specific pharmaceutical derivatives |
6.3 What are potential patentability considerations today?
- Modern process innovations can circumvent the original patent claims through alternative synthesis routes.
- Patents claiming novel compounds derived from these intermediates are not infringements but might build upon the same chemical frameworks.
- Ensuring freedom to operate involves analyzing both the expired process patent and subsequent process or compound patents.
7. The Impact on Pharmaceutical Development
| Impacted Drug Classes |
Key Compounds |
Patent Influence |
| Antifungals |
Clotrimazole, Miconazole |
Derived from heterocyclic intermediates |
| Antihypertensives |
Enalaprilate, Labetalol |
Use of heterocycles synthesized via similar processes |
| Analgesics |
Tramadol (partial heterocycle involvement) |
Synthesis processes derived from earlier patents |
The patent contributed systematically to process development, enabling later, more efficient synthesis routes.
Key Takeaways
- U.S. Patent 3,885,046 broadly claims methods for synthesizing heterocyclic pharmaceutical intermediates, primarily via halogenation and cyclization.
- Its claims, drafted in process language, historically impacted the development of heterocycle-based drugs, aligning with industry standards of the 1970s.
- The patent has expired since the early 1990s, facilitating free use of the described processes, though subsequent patents have advanced the field with innovative techniques.
- The patent landscape remains active, especially in jurisdictions like Europe and Asia, where process improvements and novel compounds continue to be patented.
- Modern synthesis techniques, including green chemistry and flow processes, have evolved beyond the scope of 3,885,046, promoting more efficient, sustainable manufacturing.
FAQs
Q1: How does U.S. Patent 3,885,046 influence current drug manufacturing?
A1: Since it expired in 1992, it no longer restricts synthesis processes. The patent historically provided foundational methods for heterocyclic intermediate production used in various pharmaceuticals.
Q2: Can companies still patent similar heterocycle synthesis processes today?
A2: Yes, if they employ distinct reaction conditions, catalysts, or novel pathways not disclosed in the expired patent, they may obtain new patents.
Q3: Are the claims of this patent enforceable against infringing processes?
A3: No, the patent has been expired for decades, eliminating enforceability but serving as prior art for future patent prosecution.
Q4: Which industries primarily relied on the process described in 3,885,046?
A4: The pharmaceutical industry, especially in manufacturing antifungal, antihypertensive, and analgesic compounds involving heterocyclic intermediates.
Q5: How has the patent landscape evolved around heterocyclic synthesis since this patent?
A5: It has seen continuous innovation through process improvements, greener techniques, and diversification of heterocycle structures, with newer patents focusing on efficiency, sustainability, and expanding chemical space.
References
[1] United States Patent and Trademark Office (USPTO). Patent Public PAIR, 1975.
[2] Patent family data and Japanese/EU counterparts accessed via Espacenet.
[3] Industry reviews on heterocyclic synthesis, Journal of Organic Chemistry, 2020.
[4] Patent document analysis methodology, PatentScope, WIPO, 2022.
This comprehensive review provides a clear understanding of the scope, claims, and patent landscape relevant to U.S. Patent 3,885,046, supporting strategic decision-making in pharmaceutical IP management.
More… ↓
⤷ Start Trial
|
